Disclaimer

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

FORWARD-LOOKING STATEMENTS

Some information contained in this presentation contains forward-looking statements. These forward-looking

Contents

1 Company Highlights

2 Business Review

3 Financial Review

4 Outlook

5 Appendix Financial Statements

Ambitious pursuit of innovation for 24 consecutive years

Core Business

Total cardio solutions

Other sectors covering main clinical specialties

Partnerships with global leading KOLs and MedTech firms

Unswervingly invested in R&D for 24 years

MicroPort微创

Global leading medical devices company

Uncompromising in quality and relentless pursuit of excellence

Industry leading commercialization capabilities

Building a super-conglomerate of people centric enterprises of EMERGING MEDICAL TECHNOLOGIES

Cardiovascular

- **Top 2** global player & **Top 1** Chinese player
- DES no. of implantation exceeded **7.5mn** units, covering **~40** countries around the globe

Endovascular

- **Top 1** Chinese player & **Top 5** global player
- **5 CE Markings** in total
- Products entered **18** overseas countries

Surgical Robot

- **only** company covering **all 5 major & fast-growing clinical specialties**
- **2rd** & Chinese **1st** laparoscopic surgical robot completing complex procedures in thoracic, abdominal & pelvic cavities
- **1st** Chinese-developed surgical robot submitted for **FDA**
- **1st** percutaneous surgical robots launching clinical trials in China
- Successful **HKEx** listing

Electro-physiology (EP)[1]

- **TOP 1** Chinese 3D catheter RF ablation player
- **One** of few global players with all-around EP solutions; entered **22** overseas countries
- **20,000+** 3D navigation cases performed
- SSE STAR **IPO** application in progress

Neurovascular

- **Top** global & **Largest** Chinese neuro-interventional player
- **FDA, CE & MDFS** approved and commercialized products with continuous overseas implantation
- HKEx **IPO** application in progress

Orthopedics & Sports Medicine

- **Top** global player with market share increase in China
- **1st** long-term implantable rotator cuff spacer system launched clinical trails

Outstanding performance amid COVID across all segments

2021A Financials

Revenue
$778.6mn ↑ 15.0%YOY

- CRM & Ortho Int'l ↑ 14.5%YOY
- Other Int'l subs ↑ 25.8%YOY

Surgical Robot
Realized revenue for the first time
R&D and marketing expenditure: **$80.1mn**

Heart Valve
$31.3mn ↑ 93.2%YOY
R&D and marketing expenditure: **$41.6mn**

Cardiovascular
$139.5mn 10.8%YOY
Impact of VBP on gross profit: **$36.8mn**
Firehawk® large-scale overseas clinical trials

International Business
Market development & product promotion expenditure: **65.2mn**[2]
- Bluetooth® pacemakers approved; Invicta
Ortho int'l - gross profit margin increased

Non-cash/ One-off Costs
$119.8mn
Incentive shares to employees: **$94.5mn**
Subsidiaries IPO costs: **$12.9mn**
CB interest accrual: **$12.4mn**

Business Highlights

Total Cardio

Cardiovascular: revenue **$139.5mn**, down 10.8% YOY
- DES volume: **1.22mn** units (**+132%** YOY)
- Balloon & accessories revenue: **+47.5% YOY**
- **OCT** & **DSA** successfully launched

CRM: revenue **$220.4mn**, **+18.8%** YOY
- Revenue **+53.7%** in China, market share ranks **Top 4**

Heart Valve: revenue **+93.2%** YOY; gross margin **+15 ppts**

EP[3]**:** revenue

Endovascular: revenue **$106.0mn**, **+45.6%** YOY
- Rapid revenue & profit growth for **5** consecutive years

Neurovascular: revenue **$59.1mn**, **+72.5%** YOY

Surgical robots: **Toumai®** approved; **Honghu** submitted to NMPA & FDA; established **10+** training centers & trained **~300** surgeons

Orthopedics: revenue **$215.6mn**, **+5.1%** YOY
- Joint products won tendors in national VBP
- Spine & Trauma revenue **+47.4%** YOY

Surgical business: revenue **$4.7mn**, **+11.6%** YOY

R&D Progress

22 NMPA, 15 CE & **7 FDA** newly obtained
26 NMPA Green Path products - **No.1** in industry

Strong Balance Sheet

Period end cash balance: $1.75bn

Note: 1. Revenue growth rate adjusted to exclude foreign exchange impact; 2. Being the

3. Electrophysiology (EP) business under associated company

Global business developed rapidly through great strategic layout

80+
Countries & Regions

20,000+
Hospitals

6,800+
Patents
(incl. applications)



India

Launched Firehawk IN as first local manufactured DES in overseas market

Further explore India market by leveraging on strong local business channels & manufacturing expertise

US

Established new HQ for the Americas, cementing MicroPort® US Strategic Triangle

Advance clinical registration and commercialization of multiple innovative products

Overseas Revenue Growth

Overall: South America **+29.9%,** EMEA **+16.8%,** North America **+6.7%**

Cardiovascular: EMEA **+136%,** South America **+18%**

CRM: EMEA **+13.3%,** Japan **+127.2%**

Orthopedics: EMEA **+27.6%,** US **+6.7%,** Japan **+6.7%**

Endovascular: **>100%**

Business Expansion

Cardiovascular: launched India manufacturing for **Firehawk** ; established new **US HQ**

Endovascular: covering **18** overseas markets, expanding to EU, South America and Asia-pacific (excl. China)

Neurovascular: multiple overseas implantations for NUMEN® in **Chile**

Heart Valve: multiple overseas implantations for VitaFlow® in **Argentina**

R&D Achievements

Newly obtained **7 FDA** & **15 CE**

Firehawk® TARGET trials for **FDA** proceeded well

Invicta ICD lead completed clinical trails & submitted **CE**

NUMEN® approved by **CE, FDA & MFDS**

approved in Argentina & submitted **CE**

Honghu submitted for **FDA**

Note: 1. Revenue growth rate adjusted to exclude foreign exchange impact

Pr

31 March6 R

~$1JETQ EMC /P ≥93 l 1 qf* Bn 05-0 960 540 reW* nBT/F1 15.86 Tf1 0 0 1 322.32 442.87 Tm0.498 g0.498 G[(e)(ta)]540 reW* nBT/F1 15.84 Tf1 0 0 1 85

Application
for listing

Mi

Enhance growth potential with strategic investment across the value chain

Strategic collaboration with leading companies around the globe

1Q 2021

Surgical Robot

MEDBOT

Robocath NDR biobot

Established JVs with **Robocath**, **NDR** and **Biobot** respectively

Further explore surgical robot business in Greater China

May 2021

Neurovascular

RAPIDMEDICAL

Led **$50mn** investment in Israel company **Rapid Medical**

Granted exclusive commercial rights for three flagship products in Greater China

Jul 2021

Heart Valve

MicroPort 心通医疗

VALCARE

Follow-on Investment of **$2.5mn** in mitral and tricuspid valve company **Valcare**

Further promote development progress of

Aug 2021

Oct 2021

Cardiovascular

Acquired **51%** equity **in Argus** for **$58mn** and become the largest shareholder

OCT Device (**CE/NMPA** approved)

Oct 2021

Surgical device

hemovent

Acquired **Hemovent 100%** equity for **$140mn**

Flagship product - portable ECMO **MOBYBOX®** (CE certified)

Long-term strategic layout to deeply explore EU market

Sep 2021

Cardiovascular

Acquired **45%** equity of **Kerui Pharma** (as major rapamycin API supplier) for **$17mn**, becoming the largest shareholder

Enhance the sustainability supply chain management system

Distinguished product highlights and clinical progress

Domestic

Cardio-vascular

Firesorb® completed patient enrollment for FUTURE-III Pivotal Trial
First DSA system **Soul-Man** obtained **NMPA**

Ortho-pedics

Zirconium Niobium Alloy Femoral Head entered **NMPA Green Path**
5 products obtained **NMPA**

Endo-vascular

Talos® Thoracic Stent Graft, **Fontus®** Surgical Stent Graft, **Ryflumen®** High-pressure Balloon Catheter obtained **NMPA**
First venous stent **Vflower®** entered **NMPA Green Path**

NUMEN® Silk 3D Electronically Detachable Coil, **Neurohawk®** Stent Thrombectomy Device, **Diveer** Intracranial Balloon Dilatation Catheter obtained **NMPA**
Tigertriever® Revascularization Device, **X-track** Intracranial Distal Access Catheter submitted for NMPA

Contents

1 Company Highlights

2 Business Review

3 Financial Review

4 Outlook

5 Appendix Financial Statements

CRM business





Top 1
Chinese player
No. 1
market share for China-made products

Product Pipeline for Non-China Business



Product Pipeline for China Business



MicroPort微创

Note: Revenue growth rate adjusted to exclude foreign exchange impact

Endovascular business

Key Financials



Overseas

	Product	Pre-clinical	Clinical	Registration
Aortics Stents	Talos® Thoracic Stent Graft System			NMPA approved in Jan-2022
	Branched Aortics Stent Graft System		Design validation	
Peripheral Products	High-pressure Balloon Catheter			NMPA approved
	Drug Balloon Catheter		Design validation	
	Vflower® Venous Stent System		Under clinical trail	
	Vena Cava Filter		Upon clinical trail	
	Thrombectomy Catheter		Upon clinical trail	
Surgical	Fontus® Branched Surgical Stent Graft System			NMPA approved
Oncolo-gical	TIPS Stent Graft System		Design validation	

Product admitted to NMPA Green Path

MicroPort微创 Note: Revenue growth rate adjusted to exclude foreign exchange impact

nically Detachable Coil	-	2nd generation of NUMEN coil family **NMPA approved in Feb-2022**
Comaneci®		

Heart valve business

Financial Highlights



IPO

- **Successful spin-off and separate listing on HKEx** (4 Feb 2021)
- **Net IPO proceeds: HKD 2,717.2mn** (~$357mn)

MicroPort 心通医疗 2160.HK

Strategic Investment

- Follow-on investment of approximately **$3.3mn** in **Valcare**, to accelerate R&D of its mitral and tricuspid product candidates, namely , **Helios** &
- Follow-on investment of **$25mn** in **4C Medical** and be granted exclusive China commercial rights for its tricuspid product

Business Highlights

Market strategy & Hospital Coverage

R&D Progress

MicroPort微创

Note: Revenue growth rate adjusted to exclude foreign exchange impact

Heart v)

	Product	Pre-clinical	Clinical	Registration
TAVI (aortic valve)	VitaFlow Liberty	**NMPA approved in Aug 2021** **Submitted for CE in Dec 2021**		
	VitaFlow® III	Design fixing		
	VitaFlow® Balloon Expandable	Design stage		
TMV (mitral valve)	In-house Developed Replacement Product	Under animal studies		
		Under early feasibility study		
	Helios	Under animal studies		
	In-house Developed Edge to Edge	Design fixing		
		Under clinical trial		
TTV (tricuspid valve)	Trivid Repair Product	Design stage		
	Edge to Edge Repair Product	Design stage		
Surgical	Surgical Valve	Design stage		
Procedural Accessories	Alwide® Plus Balloon Catheter	**NMPA approved in Jul 2021**		
	Angelguide® Tip Pre-shaped Super Stiff Guidewire	**NMPA approved in Aug 2021**		
	Alwide Balloon Catheter III	Verification stage		
	Embolic Protection Device	**Design fixing**		
	Expandable Sheath	Design stage		

Product admitted in NMPA Green Path

Surgical robot business

IPO MEDBOT™

- **IPO on HKEx on Nov 2, 2021**
  - **First surgical robot company** listing on HKEx
  - Selected for inclusion in **Hang Seng Composite Index** (Mar-22)

Business Highlights

- **DFVision®** 3D Electronic Laparoscope **approved by NMPA**; successful commercial launch with revenue contribution for the first time
- Established **10+** training centers nationwide in 2021, mainly through collaboration with reputable hospitals

R&D Progress

Laparoscopic Surgery

- Flagship product **Toumai®** Laparoscopic Surgical Robot **approved by NMPA** (Jan-22), as the **first commercialized** four-arm laparoscopic surgical robot developed in China
- Toumai® completed multi-disciplinary & multi-center clinical trial surgeries in Jan-22
- Toumai® Single-arm launched clinical trials (FIM)

Orthopedic Surgery

- Honghu in **NMPA** registration stage; submitted for **FDA** approval

Panvascular & Percutaneous Surgery

- R-One & Mona Lisa both launched NMPA registrational clinical trials

Natural Orifice Surgery

- Trans-bronchial Surgical Robot launched clinical trials (FIM)

	Product	Pre-clinical	Clinical	Registration
Laparoscopic	Toumai® Laparoscopic Surgical Robot			Obtained NMPA approval in Jan-22
Laparoscopic	DFVision® 3D Electronic Laparoscope			Obtained NMPA approval
Laparoscopic	Toumai® Single-arm Laparoscopic Surgical Robot			First human clinical trial (FIM)
Orthopedic	Honghu Orthopedic Surgical Robot			NMPA registration stage Submitted for FDA approval
Orthopedic	Spine Surgical Robot			Design stage
Natural Orifice	Trans-bronchial Surgical Robot			First human clinical trial (FIM)
Panvascular	R-One Vascular Interventional Surgical Robot			Clinical trial stage in China Obtained CE in 2019
Panvascular	TAVR Surgical Robot			Design stage
Percutaneous	Lisa Robotic Transperineal Prostate Biopsy System Mona Lisa			Clinical trial stage in China Obtained CE & FDA in 2017
Percutaneous	Automated Needle Targeting			Design stage in China Obtained CE[1] in 2020

Product admitted in NMPA Green Path

Note: 1. For the indication in percutaneous nephrolithotomy

Orthopedics business

Non-China Business Highlights

Revenue



Revenue Breakdown by Region



Revenue Growth
EMEA: +27.6%
Japan: +6.7%
US: +6.7%

- **21A revenue $193.3mn, up 11.8% YOY**
- Sales in EMEA +27.6%, US +6.7%, Japan +6.7%
- Achieved **Q4 breakeven** in P&L with **positive free cashflow**

Cost Savings

- Achieved over **$4.6mn cost savings** with completion of **40+** cost improvement projects, including cross-border manufacturing collaboration and streamlining of operation teams
- Transferred partial manufacturing process to China to leverage global **capabilities**

R&D Progress

- **5 CE** & **5 FDA** key product approvals
- Cooperated with various partners for development of surgical imaging and planning

Joints

- **21A revenue $14.6mn**; decrease caused by reduced orders due to VBP policy
- Hip and knee products won national **VBP tenders**, with guaranteed volume of **~15,000** units (**~3%** of total procurement volume)
- Penetrated 700+ hospitals with total coverage of 1,400+ hospitals
- **Advance®** Medial-Pivot Knee System received **15 ODEP** (Orthopedic Data Evaluation Panel) **1st Chinese company** to receive the **highest** ODEP rating
- **5** products newly **approved by NMPA**; self-developed Zirconium niobium alloy femoral head (new material) entered **NMPA Green Path**

Spine & Trauma

- **21A revenue $5.5mn, up 47.4% YOY**
- Robust sales growth driven by **markets expansion** & **new product launches**
- Won tender of trauma volume-based procurement of 12 provinces league

Note: 1. Revenue growth rate adjusted to exclude foreign exchange impact; 3. All R&D progresses until the end of Mar-22



Contents

1 Company Highlights

2 Business Review

3 Financial Review

4 Outlook

5 Appendix Financial Statements

Consolidated financial performance

Gross Profit Margin

Operating expenses

Sales & Marketing Expenses

USD: million

Sales & marketing expenses increased by 17.1%YOY

- Increase in marketing activities as Covid-19 pandemic came under control

Administrative Expenses

USD: million

Administrative expenses increased by 47.0%YOY

- Increase in staff costs including share based payment

R&D Expenses

USD: million

R&D expenses increased by 54.6%YOY

- Due to increased investments in R&D projects

Contents

1 Company Highlights

2 Business Review

3 Financial Review

4 Outlook

5 Appendix Financial Statements

Innovative product pipeline fueling long-term growth

Cardio-vascular	**Firehawk® Plus** *NMPA&CE*	**Firesorb® Bioresorbable Scaffolds** *NMPA&CE*	**Coronary Stent Graft System** *NMPA*	**Pro/NC Pro** *NMPA*	**Rapamycin Drug-coated Balloon** *NMPA&CE*	**Coronary Rotational Atherectomy System** *NMPA&CE*	**Firehawk®** *FDA*	**Intravascular Lithotripsy Balloon** *NMPA&CE*
Orthopedics	**VenusOne Acetabular System** *NMPA*	**Evolution Medial Pivot Knee® Localization** *NMPA*				**2D-to-3D Imaging Technology** *FDA*		
CRM	**Rega® Pacemaker & BeFlex (MRI OOC)** *NMPA*	**Ulys Edis Gali ICD/CRT-D (MRI)** *CE*	**Invicta (MRI)** *CE*	**Lead**		**Pacemaker & BonaFire Passive Lead (MRI)** *NMPA*	**Platinium ICD/CRT-D** *NMPA*	**Leadless Pacemaker** *NMPA&CE* 
Endo-vascular	**Vflower® Venous Stent System** *NMPA* 	**Vena Cava Filter** *NMPA*	**Thrombectomy Catheter** *NMPA*			**Drug Balloon Catheter** *NMPA*	**Branched Aortics Stent Graft System** *NMPA*	**TIPS Stent Graft System** *NMPA*
Neuro-vascular	**Tigertriever Revasculari-zation Device** *NMPA*	**X-Intracranial Distal Access Catheter** *NMPA*	**Comaneci® Embolization Assist Device** *NMPA*			**Rebridge® Intracranial Visualized Stent** *NMPA*	**-diverting Stent** *NMPA*	**Balloon Protection Guiding Catheter** *NMPA*
Heart Valve	**VitaFlow® III** *NMPA*	**VitaFlow® Balloon Expandable** *NMPA*	**Mitral Replacement:** **AltaValve** **Helios** **In-house Developed Replacement Product**	**Mitral Repair:** **In-house Developed Edge to Edge Repair Product**		**Tricuspid Repair:** **Trivid Repair Product** **Edge to Edge Repair Product**	**Surgical Valve** *NMPA*	**Embolic Protection Device** *NMPA*
Surgical Robot	**Honghu Orthopedic Surgical Robot** *NMPA & FDA*	**Toumai® Single-arm Laparoscopic Surgical Robot** *NMPA*	**R-Interventional Surgical Robot** *NMPA*			**Robotic Transperineal Prostate Biopsy System** *NMPA*	**Trans-bronchial Surgical Robot** *NMPA* **TAVR Surgical Robot** *NMPA*	**Spine Surgical Robot** *NMPA*
Surgical Devices	**VitaSprings Membrane Oxygenator** *NMPA*	**Femoral Arterial &Venous Cannula** *NMPA*	**Arterial Micro-Embolic Filter (new type)** *NMPA*			**ECMO** *NMPA*	**MOBYBOX System** *NMPA*	
Electro-physiology[1]	**High Density Mapping Catheter** *NMPA*	**Contact Force-Sensing Catheter** *NMPA*	**Cryoablation Catheter** *NMPA*			**IceMagic® Cardiac Cryoablation System** *NMPA*	**Renal RF Ablation System** *NMPA*	**Flashpoint® Renal Artery Ablation Catheter** *NMPA*

Note: 1. Electrophysiology business under associated company

Contents

1 Company Highlights

2 Business Review

3 Financial Review

4 Outlook

5 Appendix Financial Statements

Appendix I - Consolidated Income Statement

USD'000	2021	2020	Var.
Revenue	778,639	648,732	20.0%
Cost of sales	(286,866)	(212,700)	34.9%
Gross profit	**491,773**	**436,032**	**12.8%**
Other net income	76,475	32,924	132.3%
Research and development costs	(297,778)	(192,629)	54.6%
Distribution cost	(297,532)	(254,105)	17.1%
Administrative expenses	(250,010)	(170,105)	47.0%
Other operating costs	(16,547)	(19,678)	-15.9%
Loss from operations	**(293,619)**	**(167,561)**	**75.2%**
Finance cost	(47,883)	(39,712)	20.6%
Gain on deemed disposal of a subsidiary	8,218	-	N/A
Gain on deemed disposal of interest in equity-accounted investees	9,215	1,062	767.7%
Share of losses of equity-accounted investees	(13,255)	(6,730)	97.0%
Loss before taxation	**(337,324)**	**(212,941)**	**58.4%**
Income tax	(13,971)	(10,407)	34.2%
Loss for the period	**(351,295)**	**(223,348)**	**57.3%**
Attributable to: Equity shareholders of the Company	**(276,484)**	**(191,252)**	**44.6%**

Appendix II - Consolidated Balance Sheet

USD'000	31 Dec 2021	31 Dec 2020	Var.
Non-current assets			
Investment properties	7,407	5,284	40%
Other property, plant and equipment	922,874	481,203	92%
Intangible assets	256,609	138,397	85%
Prepayments for non-current assets	18,159	7,724	135%
Goodwill	290,565	159,483	82%
Equity-accounted investees	363,103	87,063	317%
Other financial assets	30,184	19,605	54%
Deferred tax assets	20,368	15,502	31%
Other non-current assets	84,493	75,009	13%
Total non-current assets	**1,993,762**	**989,270**	**102%**
Current assets			
Inventories	289,931	240,187	21%
Trade and other receivables	308,126	236,976	30%
Pledged deposits and time deposits	32,890	623	5179%
Cash and cash equivalents	1,754,414	1,002,077	75%
Derivative financial assets	1,406	-	N/A
Total current assets	**2,386,767**	**1,479,863**	**61%**
Current liabilities			
Trade and other payables	358,792	372,472	-4%
Contract liabilities	23,590	62,008	-62%
Lease liabilities	50,505	12,074	318%
Interest-bearing borrowings	94,746	10,891	770%
Income tax payable	19,124	52,682	-64%
Derivative financial liabilities	-	9,252	-100%
Total current liabilities	**546,757**	**519,379**	**5%**
Net current assets	**1,840,010**	**960,484**	**92%**

Appendix II - Consolidated Balance Sheet

USD'000	31 Dec 2021	31 Dec 2020	Var.
Non-current liablities			
Interest-bearing borrowings	269,637	181,988	48%
Lease liabilities	168,437	42,774	294%
Deferred income	35,098	37,844	-7%
Convertible bonds	660,369	48,583	1259%
Contract liabilities	26,243	29,855	-12%
Other payables	425,914	203,023	110%
Deferred tax liabilities	27,692	4,122	572%
Derivative financial liabilities	2,890	13,619	-79%
Total non-current liablities	**1,616,280**	**561,808**	**188%**
CAPITAL AND RESERVE			
Share capital	18	18	-
Reserves	1,490,732	1,127,945	32%
Total equity attributable to equity shareholders of the Company	**1,490,750**	**1,127,963**	**32%**
Non-controlling interests	726,742	259,983	180%
Total equity	**2,217,492**	**1,387,946**	**60%**

Disclaimer

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

FORWARD-LOOKING STATEMENTS

Some information contained in this presentation contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China and other countries that MicroPort operates in.

CONFIDENTIALITY

This presentation is confidential and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose.